These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
719 related articles for article (PubMed ID: 24310455)
1. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center. Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455 [TBL] [Abstract][Full Text] [Related]
2. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670 [TBL] [Abstract][Full Text] [Related]
3. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. Kiriyama T; Kataoka H; Taoka T; Tonomura Y; Terashima M; Morikawa M; Tanizawa E; Kawahara M; Furiya Y; Sugie K; Kichikawa K; Ueno S J Neuroimaging; 2011 Apr; 21(2):e69-77. PubMed ID: 20572907 [TBL] [Abstract][Full Text] [Related]
4. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924 [TBL] [Abstract][Full Text] [Related]
5. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Lebrun C; Bensa C; Debouverie M; Wiertlevski S; Brassat D; de Seze J; Rumbach L; Pelletier J; Labauge P; Brochet B; Tourbah A; Clavelou P; Arch Neurol; 2009 Jul; 66(7):841-6. PubMed ID: 19597085 [TBL] [Abstract][Full Text] [Related]
6. Benign course of tumour-like multiple sclerosis. Report of five cases and literature review. Turatti M; Gajofatto A; Bianchi MR; Ferrari S; Monaco S; Benedetti MD J Neurol Sci; 2013 Jan; 324(1-2):156-62. PubMed ID: 23151425 [TBL] [Abstract][Full Text] [Related]
7. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology. Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252 [TBL] [Abstract][Full Text] [Related]
9. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556 [TBL] [Abstract][Full Text] [Related]
10. Conventional and advanced magnetic resonance imaging in tumefactive demyelination. Saini J; Chatterjee S; Thomas B; Kesavadas C Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739 [TBL] [Abstract][Full Text] [Related]
11. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand. Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919 [TBL] [Abstract][Full Text] [Related]
12. Demyelinating lesions in the cervical cord in multiple sclerosis 10 years after onset of the disease. Correlation between MRI parameters and clinical course. Bonek R; Orlicka K; Maciejek Z Neurol Neurochir Pol; 2007; 41(3):229-33. PubMed ID: 17629816 [TBL] [Abstract][Full Text] [Related]
13. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666 [TBL] [Abstract][Full Text] [Related]
14. Tumour-like lesions in multiple sclerosis. Jamroz-Wiśniewska A; Janczarek M; Belniak E; Stelmasiak Z; Bartosik-Psujek H Neurol Neurochir Pol; 2008; 42(2):161-7. PubMed ID: 18512174 [TBL] [Abstract][Full Text] [Related]
15. Tumefactive demyelinating lesions: A comprehensive review. Algahtani H; Shirah B; Alassiri A Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436 [TBL] [Abstract][Full Text] [Related]
16. Clinical isolated syndrome: a 3-year follow-up study in China. Liu Y; Duan Y; Yu C; Qin W; Chen H; Dong H; Ye J; Butzkueven H; Li K Clin Neurol Neurosurg; 2011 Oct; 113(8):658-60. PubMed ID: 21680087 [TBL] [Abstract][Full Text] [Related]
17. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis. Dalton CM; Bodini B; Samson RS; Battaglini M; Fisniku LK; Thompson AJ; Ciccarelli O; Miller DH; Chard DT Mult Scler; 2012 Mar; 18(3):322-8. PubMed ID: 21878451 [TBL] [Abstract][Full Text] [Related]
18. [The clinical features, neuroimaging findings and pathological characteristics of 26 patients with pathologically proven tumor-like inflammatory demyelinating diseases]. Qi XK; Liu JG; Qian HR; Qiu F; Yao S; Li CQ; Wang YM Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):750-3. PubMed ID: 21092444 [TBL] [Abstract][Full Text] [Related]